Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo

Journal of Thoracic and Cardiovascular Surgery

Volumn 117, Issue 4, 1999, Pages 803-809

  Videm, V ^a   Mollnes, T E ^a   Bergh, K ^a   Fosse, E ^a   Mohr, B ^a   Hagve, T A ^a   Aasen, A O ^a   Svennevig, J L ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; AORTA OCCLUSION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; ELECTIVE SURGERY; ENZYME IMMUNOASSAY; EQUIPMENT; FEMALE; HEART SURGERY; HUMAN; MALE; PRIORITY JOURNAL; SAFETY; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; VARIANCE;

EID: 0032905916     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(99)70302-8     Document Type: Article

References (26)

1. V Videm JL Svennevig E Fosse G Semb A østerud TE Mollnes Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations J Thorac Cardiovasc Surg 103 1992 806 813
2. O Moen K Høgåsen E Fosse E Degrelid V Brockmeier P Venge Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass Ann Thorac Surg 63 1997 105 111
3. M Fukutomi S Kobayashi K Niwaya Y Hamada S Kitamura Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment Artif Organs 20 1996 767 776
4. V Videm TE Mollnes E Fosse B Mohr K Bergh TA Hagve Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population J Thorac Cardiovasc Surg 117 1999 794 802
5. TE Mollnes P Garred G Bergseth Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation Clin Exp Immunol 73 1988 484 488
6. H Fure EW Nielsen CE Hack TE Mollnes A neoepitope based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s Scand J Immunol 46 1997 553 557
7. TE Mollnes Analysis of in vivo complement activation 5th ed LA Herzenberg DM Weir LA Herzenberg C Blackwell Weir's handbook of experimental immunology Volume 78 1997 Blackwell Science Boston 78.1 788
8. K Bergh OJ Iversen Production of monoclonal antibodies against the human anaphylatoxin C5a desArg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a desArg in plasma J Immunol Methods 152 1992 79 87
9. W van Beaumont Evaluation of hemoconcentration from hematocrit measurements J Appl Physiol 32 1972 712 713
10. RS Bonser JR Dave L John MK Gademsetty PG Carter E Davies Complement activation before, during and after cardiopulmonary bypass Eur J Cardiothorac Surg 4 1990 291 296
11. UR Nilsson O Larm B Nilsson KE Storm H Elwing K Nilsson Ekdahl Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment Scand J Immunol 37 1993 349 354
12. GB Caughman RJ Boackle J Vesely A postulated mechanism for heparin's potentiation of C1 inhibitor function Mol Immunol 19 1982 287 295
13. H te Velthuis PGM Jansen E Hack L Eijsman CRH Wildevuur Specific complement inhibition with heparin-coated extracorporeal circuits Ann Thorac Surg 61 1996 1153 1157
14. E Fosse S Thelin JL Svennevig P Jansen TE Mollnes E Hack Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect release of granulocyte enzymes in fully heparinized patients: a European multicentre study Eur J Cardiothorac Surg 11 1997 320 327
15. NC Cavarocchi HV Schaff TA Orszulak HA Homburger WA Schnell JR Pluth Evidence for complement activation by heparin-protamine interaction after cardiopulmonary bypass Surgery 98 1985 525 531
16. RS Bonser J Dave J Morgan C Morgan E Davies P Taylor Complement activation during bypass in acquired C1 esterase inhibitor deficiency Ann Thorac Surg 52 1991 541 545
17. S Bhakdi W Fassbender F Hugo MP Carreno C Berstecher P Malasit Relative inefficiency of terminal complement activation J Immunol 141 1988 3117 3122
18. RJ Boackle GB Caugham J Vesely G Medgyesli HH Fudenberg Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway Mol Immunol 20 1983 1157 1164
19. F Maillet MD Kazatchkine D Glotz E Fisher M Rowe Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b Mol Immunol 20 1983 1401 1404
20. PJ Baker TF Lint BC McLeod CL Behrends H Gewurz Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis by polyanions and polycations J Immunol 114 2 Pt 1 1975 554 558
21. T Yatohgo M Izumi H Kashiwagi M Hayashi Novel purification of vitronectin from human plasma by heparin affinity chromatography Cell Struct Funct 13 1988 281 292
22. TE Mollnes J Riesenfeld P Garred E Nordström K Høgåsen E Fosse A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin Artif Organs 19 1995 909 917
23. TE Mollnes V Videm O Götze M Harboe M Oppermann Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin Ann Thorac Surg 52 1991 92 97
24. V Videm TE Mollnes P Garred JL Svennevig Biocompatibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits J Thorac Cardiovasc Surg 101 1991 654 660
25. G Hetland O Moen K Bergh K Høgåsen CE Hack TE Mollnes E Fosse Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo Ann Thorac Surg 63 1997 1076 1080
26. TE Mollnes Early- and late-phase activation of complement evaluated by plasma levels of C3dg and the terminal complement complex Complement 2 1985 156 164